Tech Company Financing Transactions
Leap Therapeutics Funding Round
Leap Therapeutics, based in Cambridge, raised $58.9 million from Winklevoss Capital and private investors.
Transaction Overview
Company Name
Announced On
10/9/2025
Transaction Type
Venture Equity
Amount
$58,900,000
Round
Undisclosed
Investors
Winklevoss Capital (Lead Investor)
Proceeds Purpose
Winklevoss Capital will provide capital and strategic support for Leap's digital asset treasury strategy, according to the company's statement.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47 Thorndike St
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Not Recorded
Overview
Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Onsi
Browse more venture capital transactions:
Prev: 10/8/2025: EvenUp venture capital transaction
Next: 10/9/2025: FurtherAI venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs